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Background 
The oral anticoagulant apixaban is becoming a popular first-line option for prevention of stroke and 
systemic embolism, in adults with non-valvular atrial fibrillation (NVAF) exhibiting one or more risk 
factors. Two dosage regimens are recommended: 5mg twice daily or 2.5mg twice daily; the latter is 
deemed appropriate if creatinine clearance (CrCl) 15-POPLQRUDWOHDVWWZRRIDJH\HDUVERG\
ZHLJKWNJRUVHUXPFUHDWLQLQH micromol/L are satisfied. These criteria derive from results 
of two large successful clinical trials1,2 and have formed the basis of local prescribing guidelines. 
Objectives 
x To audit against the following standard: 
o 95% of patients prescribed apixaban for NVAF should be assigned a dose in terms of 
weight, age and renal function in accordance with local guidelines. 
x To analyse dose reduction criteria met by patients to ascertain why their prescribed doses were 
inappropriate 
x To identify any significant differences in adherence to guidelines according to gender and age. 
x To identify any differences to dose recommendations when different measures of renal function 
(CrCl based on actual body weight, CrCl based on ideal body weight and estimated Glomerular 
Filtration Rate [eGFR]) are used. 
x To review audit results and make recommendations for future practice. 
Method 
Patients discharged from cardiology wards between 8th June and 8th December 2015 who were 
prescribed apixaban for NVAF were included in this audit. A data collection form was developed to 
gather relevant data, which included age, weight, height, creatinine and eGFR. Data was collected 
UHWURVSHFWLYHO\XVLQJ&OLQLFDO3RUWDODQG7UDNFDUH0LFURVRIW([FHODQG0LQLWDEVRIWZDUHZHUHXVHG
to analyse compound data and generate relevant statistics. This audit did not require ethics approval. 
Results 
Of the 104 patients identified, six patients could not be assessed due to missing data. Approximately 
three quarters (73%) of the remaining patients were prescribed an appropriate dose according to 
guidelines. No significant differences in adherence rates were found between males and females 
(p=0.209) or between patients aged 80 or over and patients aged 79 or under (p=0.161). The majority 
of patients (68%) prescribed a subtherapeutic dose were aged 80 or over, indicating that age was a 
SRWHQWLDOFRQWULEXWLQJIDFWRUIRUµXQGHUGRVLQJ¶SDWLHQWV7KHUHZHUHPLQRUGLIIHUHQFHVLQWKH rates of 
recommended dose reductions when applying different measures of renal function (range: 21 - 26.5%). 
Conclusions 
This audit has shown that current evidence-based guidelines are not being fully adhered to, especially 
when prescribing for elderly patients. 
Consequently, these patients are potentially put at risk of subtherapeutic dosing, in turn increasing their 
probability of stroke. Current published evidence does not justify reducing doses based solely on age, 
despite anecdotal concerns of local prescribers of an increased risk of haemorrhage. 
Towle, I., Jacqueline, S., & Pernille, S. (2016). An audit of apixaban prescribing for atrial fibrillation in a hospital setting. Poster session 
presented at UKCPA 2016, Manchester, United Kingdom. 
Prescribers should remain vigilant and document any reasons for dosing the product outside of its 
licence. 
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